{"name":"AOP Orphan Pharmaceuticals AG","slug":"aop-orphan-pharmaceuticals-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Brevibloc","genericName":"Brevibloc","slug":"brevibloc","indication":"Atrial fibrillation","status":"marketed"},{"name":"Anagrelide retard","genericName":"Anagrelide retard","slug":"anagrelide-retard","indication":"Essential thrombocythemia (ET) — reduction of elevated platelet counts","status":"phase_3"},{"name":"Standard of Care - Double Oral","genericName":"Standard of Care - Double Oral","slug":"standard-of-care-double-oral","indication":"Acute coronary syndrome","status":"marketed"},{"name":"preservative-free parenteral treprostinil","genericName":"preservative-free parenteral treprostinil","slug":"preservative-free-parenteral-treprostinil","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Esmolol hydrochloride, infusion","genericName":"Esmolol hydrochloride, infusion","slug":"esmolol-hydrochloride-infusion","indication":"Other","status":"phase_2"},{"name":"AOP200704","genericName":"AOP200704","slug":"aop200704","indication":"Other","status":"phase_2"},{"name":"Thromboreductin","genericName":"Thromboreductin","slug":"thromboreductin","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Peg-P-IFN-alpha-2b (AOP2014)","genericName":"Peg-P-IFN-alpha-2b (AOP2014)","slug":"peg-p-ifn-alpha-2b-aop2014","indication":"Chronic hepatitis C","status":"phase_3"},{"name":"Pegylated-Proline-interferon alpha-2b","genericName":"Pegylated-Proline-interferon alpha-2b","slug":"pegylated-proline-interferon-alpha-2b","indication":"Chronic hepatitis C","status":"phase_3"}]}],"pipeline":[{"name":"Brevibloc","genericName":"Brevibloc","slug":"brevibloc","phase":"marketed","mechanism":"Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","indications":["Atrial fibrillation","Perioperative Tachycardia","Perioperative hypertension","Supraventricular tachycardia"],"catalyst":""},{"name":"Esmolol hydrochloride, infusion","genericName":"Esmolol hydrochloride, infusion","slug":"esmolol-hydrochloride-infusion","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AOP200704","genericName":"AOP200704","slug":"aop200704","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anagrelide retard","genericName":"Anagrelide retard","slug":"anagrelide-retard","phase":"phase_3","mechanism":"Anagrelide is a phosphodiesterase 3 inhibitor that reduces platelet production by inhibiting megakaryocyte maturation and proliferation.","indications":["Essential thrombocythemia (ET) — reduction of elevated platelet counts","Polycythemia vera with thrombocytosis"],"catalyst":""},{"name":"Peg-P-IFN-alpha-2b (AOP2014)","genericName":"Peg-P-IFN-alpha-2b (AOP2014)","slug":"peg-p-ifn-alpha-2b-aop2014","phase":"phase_3","mechanism":"Peg-P-IFN-alpha-2b is a pegylated interferon alpha-2b that activates innate immune responses to suppress viral replication and enhance antiviral immunity.","indications":["Chronic hepatitis C","Chronic hepatitis B"],"catalyst":""},{"name":"Pegylated-Proline-interferon alpha-2b","genericName":"Pegylated-Proline-interferon alpha-2b","slug":"pegylated-proline-interferon-alpha-2b","phase":"phase_3","mechanism":"Pegylated-Proline-interferon alpha-2b is a modified interferon alpha-2b with extended half-life that activates innate immune responses through interferon-alpha receptor signaling.","indications":["Chronic hepatitis C","Chronic hepatitis B"],"catalyst":""},{"name":"Standard of Care - Double Oral","genericName":"Standard of Care - Double Oral","slug":"standard-of-care-double-oral","phase":"marketed","mechanism":"This is a standard-of-care dual oral antithrombotic regimen combining two antiplatelet or anticoagulant agents to prevent thrombotic events.","indications":["Acute coronary syndrome","Post-percutaneous coronary intervention","Atrial fibrillation with additional thrombotic risk"],"catalyst":""},{"name":"Thromboreductin","genericName":"Thromboreductin","slug":"thromboreductin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"preservative-free parenteral treprostinil","genericName":"preservative-free parenteral treprostinil","slug":"preservative-free-parenteral-treprostinil","phase":"phase_3","mechanism":"Treprostinil mimics the action of prostacyclin, which is a natural substance that dilates blood vessels and prevents platelet aggregation.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxORnViXzB3VVFUSjAxaVdiMDNFS2d3b1BJallZZS1LVTBrU3NDampweURKeGVtaE9oS2FPc0M0MXpYdDdRSE8tTHNCZlVFSEk1RTdrU1Qxd3p4eGMxNXlpVWlHUTlrNjV5RkJHdjhWajVnSGxzcm9wV0JkMWtBVXZwQ29qcGZlVVdIcURDdm9MbEFuZ3lENTFua2dRQlUydTZjMnVFS2FXS2I0OUpSU2R0UzBnWmZaVlZza1lnSU5YMm5vU2dBeW81bGN4cW9UY1QtdkNCMWxqMUF5WHZGWVYydDc5RWhHWUFSV0FNZTNPOFgxdw?oc=5","date":"2025-02-20","type":"regulatory","source":"globenewswire.com","summary":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - globenewswire.com","headline":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPUGV5R2wzSVBubDhBTEQzMEFhUDMtUHgxcXpXWFRORTFnbFRiM2JKeTlpY2NycDJSNkppOUFmT1diNFNxOVN5SnlTWDNRMnpBenNWYkVCS0x1UEpRQkVvYmJ6YXkxeDhqVk1Pb3VzRDkzU2VmcnRpUkcwNlUzU3NuenJaUnZyVEJQR0JIdkVFZ3ZLUjZ6Z0lKYUtDaEdfLTJKNTlkOGRYZXJ1UzhJRlNtNTB0Y3hIb2YwQVhfQVJqY2ZkR2FSOVo3MnRRV194R3NNQWJjd0c5MV81RjJWckE2aWU5cmU0OEdFMW1UMjdrWklRTkdwZm1rQ0NTNnRWRU05dFFydGkxV0k2ZXhJ?oc=5","date":"2025-02-17","type":"pipeline","source":"Business Wire","summary":"ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Business Wire","headline":"ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon al","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNQmM3OTMwZDFhQ1kySEllUjc1VlJDeTE0aWppbzRSMjU3bk1ERjc0ZEpDR3lQeE4xbjE5aFRLaV9XOWM2akJocDI0SHF1ZGxoZjhpWUQ0LTFrbkZWLXg2U2dxSVJyZkl3SzZSSDBCYzR2ZUFJRGVnZlJseS1kZVpWLVdfak5xVXc3T05RM2s4TGFRNFo2WkljX3Z5Q1dkUGFBWkgtNEZzQVhQTkl3WlpnU1M4bjJoVDlURTAtc3cxZjVPZlgxM1psOWhZaV9FVi1acnhmVmpRTDdXSFJSaUZaZFdTMnY4RVRUNUE?oc=5","date":"2022-02-16","type":"deal","source":"businesswireindia.com","summary":"German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages. - businesswireindia.com","headline":"German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOUFhSVERNN1hIUmNhZWk0NWJwbUdTenBqSW9Pa01zQ1p1TmxPMml0WEZhWFNtejFvZVFJSWR0cFRsZXFsb20zRko4aVhWT2dSakJYVGFqUnZ1aFBTRmZCNklVdnN5TjRMQXVNVFA2ODEwT3pCSnl4THZHc0lGbjYyTE1QcGJXaGdUVklZNHF5M041Tlh3STVkSzNR0gFWQVVfeXFMUHBoeEpRWmpMdmRkcUdHZHItQzQzei1NOE44QmFnazE4UWVsUGFVazlPcWRGYWZpRGUwdWZhN2tBWXBUcDdKWmN3cjZtVld2OVk1TUlmU0E?oc=5","date":"2022-01-20","type":"pipeline","source":"Law360","summary":"AOP Orphan Accuses PharmaEssentia Of Arbitration Fraud - Law360","headline":"AOP Orphan Accuses PharmaEssentia Of Arbitration Fraud - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPVGlKOG1Dd3pQeTVXWHg0R1FmM2xzcTVnc0tDT0ttRXNhd0VzZW5HdkdJMmQ3enhpdDlWQW12ZVpuYkZOVWJramF0cnUwcjQtYmpVUU14VUhYNFIxVDVsMEswR1R5NkJCNHo0cURBcHFDVlRFb0xSNHZlSk9aZFRDRU9nall5NU5QaEt4RmpMWTVKVmlkcVJLRXhRb3drQmZFS0xvc1ZscDB4RHlqclNSUg?oc=5","date":"2021-11-15","type":"regulatory","source":"Business Wire","summary":"BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA - Business Wire","headline":"BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxONWo3d3hmLVRLdm1EdXl0S0NiMUQ0V1BxWTd0cElLYnl5aVh3TG11Z21KNEl1LTFZbTRhTFZSM2UxQTA5bERXSXh2ZDlMa29lLXpTeEljcjA0NGotNkhIVWs2eHNzU2JlOC1LbmdVOUlDWEI5T18zcm5zRDc1WmkzS0N5cjcxNWlBdXRNbFZINFlZUl81bWZNdmlhcmZaUm9pa29ZdXJfOGhBNEY5ZUU5VGtBRkZrNGR1Umt4OExB?oc=5","date":"2021-11-15","type":"regulatory","source":"BioWorld News","summary":"Pharmaessentia’s Besremi approved in US for rare blood disorder polycythemia vera - BioWorld News","headline":"Pharmaessentia’s Besremi approved in US for rare blood disorder polycythemia vera","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNV3dlZURuSDFXaWpsWG02b1E3SUNmVDFJYkpndjF3cDZVT0lFQ1VMRzdnX0FGVU1sRlJSN1RCVGQ4ZE1aU0lXSUplQlVHdzFaRDdocDgwRUxMaEJLZU5yMVFha0VfSjB1TXU2ZHRLYVhjNzdvY2tWd2w3SVYzSjBBVjAtblJvVjFkbThhdkd6WWxLZHk2RGRrWE1DQmJNYk1WbFA3MFFxS1BGWkxTejZMeGRjVnpMZ0ZGeHpOR3pUMkxOSHlEc0kyZHlR?oc=5","date":"2021-03-25","type":"pipeline","source":"Business Wire","summary":"AOP Orphan reports full validity of arbitral award against PharmaEssentia - Business Wire","headline":"AOP Orphan reports full validity of arbitral award against PharmaEssentia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNLW55eHc3YjF6b0ZLdU5rZlRRd25pZGVhRDF2UUppZ2w1aVVUOVZMMVhFYldLRm55SktCck9HSG9FTGtBUVB3LTdQVjV2ckFfZDNSTGEtTU9SNEJuUXN3UTVXWmRRQVdVWXR0UXFsMTNWV1VmOGFnRExuaDZVMlpydg?oc=5","date":"2020-10-13","type":"pipeline","source":"Pf Media","summary":"AOP Orphan takes over two healthcare companies - Pf Media","headline":"AOP Orphan takes over two healthcare companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQQXF5ZDhVTW0xYjFSY2JTOEl3bll5SXlEdWdoNWowdVNJTm1SdzduZi1DTnVCNDV2RDF2LVJIb0Y2SVB3elJmTUVaZ3AtRHFkT0w3ZVhfdE9obDhrM19SOXRwWDlLeDhkcE42cmdWQXdNbkk3ajZ0RjFoZVhxYmJBNlZielNEZUxSYk40YnRrN0NnOHozYXJwUUNNNWk2UQ?oc=5","date":"2018-09-19","type":"deal","source":"PharmaTimes","summary":"Norgine buys rights to sell Shield’s iron deficiency therapy - PharmaTimes","headline":"Norgine buys rights to sell Shield’s iron deficiency therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPcFFhSndtRmNyUnp1RVUyNkMwLTJDUjUwNElXV2gxaGI4VjN5M0N2cG85LTUySUxINmZOeTNOTGU4V0I4Skp3NUc3aDJkcE0tWTFmMU5BMkMxZmJBWmFWdG1Cb2NnV1FZREpHaFltUHllR3VwdHduUUZEb3c2Sl9vMXVn?oc=5","date":"2013-07-29","type":"deal","source":"PMLiVE","summary":"Perrigo agrees $8.6bn deal to buy Elan - PMLiVE","headline":"Perrigo agrees $8.6bn deal to buy Elan","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":2,"phase_2":2,"phase_3":5},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}